Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.47 |
| ▸ | PDE4A | P27815 | 9/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | UGCG | Q16739 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5509182 | 0.94 | PDE4B (0.48) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1826949 | 0.90 | PDE4B (0.48) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL5511996 | 0.89 | PDE4B (0.51) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL13002994 | 0.89 | PDE4B (0.51) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL13165893 | 0.89 | PDE4B (0.49) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL5515932 | 0.89 | PDE4B (0.49) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL24182040 | 0.89 | PDE4B (0.49) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1826824 | 0.88 | PDE4B (0.47) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL8306055 | 0.88 | PDE4B (0.47) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL3553055 | 0.88 | PDE4B (0.47) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605896-B1 | 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2013-09-18 | — | — | EP | disclosed |
| US-7256210-B2 | 7-amido-isoindolyl compounds and methods of their use | CELGENE CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-20060058362-A1 | 7-Amido-isoindolyl compounds and methods of their use | MAN HON-WAH | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058362-A1 | 7-Amido-isoindolyl compounds and methods of their use | MCL1, APC, HPGDS | PDE4B 2106/4885PDE4C 1281/4885PDE4A 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.